Fresh analysis suggests that patients who come off blockbuster GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass much more quickly than those who end traditional lifestyle regimens.
Findings released in a major medical journal points out that while overweight people often shed a large proportion of their total mass while using the jabs, the mass is regained at an average rate of nearly a kilo each month once they quit.
"Individuals purchasing such medications need to be cognizant of the risk of quick rebound weight gain when the therapy concludes," warns lead investigator Dr. Susan Jebb.
This pace of regain means a return to original weight in about a year and a half.
Comparing Therapies
The analysis, which looked at 37 of studies involving thousands of patients, contrasted the effects of the injectable medications with conventional dieting.
The team emphasize that individuals who shed pounds through lifestyle changes alone usually have a slower creep back—around 100 grams monthly—post-intervention.
Explaining the Fast Regain
Doctors believe the mode of action of the jabs explains the accelerated weight return.
The injections mimic a natural hormone called GLP-1, which moderates appetite.
"Sustained high doses of GLP-1 concentrations far above than normal may cause the body to produce less of its own natural GLP-1, and could reduce responsiveness to its actions," explained Dr. Adam Collins, a nutrition researcher.
"Stopping of this GLP-1 'fix' means appetite is unsuppressed, making binge eating a significant risk."
A Lifelong Condition?
Health authorities recommend the jabs for individuals with obesity-related medical conditions, accompanied by recommended lifestyle changes.
Many experts contend that, considering the significant potential of relapse, the treatment is often ongoing.
This opinion is supported by pharmaceutical companies, who note that the findings "emphasize the long-term nature of obesity," similar to managing diseases like hypertension.
Patient Accounts
Individuals who have stopped the jabs explain a intense return of appetite.
"It was like a switch that goes on and you become extremely hungry," said an individual.
This challenge is compounded if users have not developed lasting lifestyle or habit modifications during therapy.
Significant Adoption
Recent estimates suggest that a significant number of people in the UK have used weight-loss jabs in the past year, with desire continuing to grow.
- Use is more common among females compared to men.
- The middle-aged age group shows the greatest usage rates.
- Many access the medications through private healthcare rather than the NHS.
In conclusion, clinicians emphasize that while the jabs are effective tools for weight loss, they are not a standalone fix and long-term success hinges on integrated lifestyle support.
